MetaVia names Sarah Browne, M.D. Chief Medical Officer; DA-1726 Phase 1 Part 3 data due Q4 2026

MetaVia Inc.

Sarah Browne, M.D. appointed Chief Medical Officer effective October 12, 2026, with more than 20 years in clinical development, regulatory science and clinical medicine.
Browne was VP of Clinical Development at Altimmune, leading pemvidutide (dual GLP-1/glucagon receptor agonist) from first-in-human through Phase 2 and an FDA End-of-Phase 2 meeting.
Earlier she was Senior Advisor for Clinical Review at the FDA's CBER and an assistant clinical investigator at NIH; she has authored 40+ peer-reviewed publications.
CEO Hyung Heon Kim said she joins as MetaVia prepares for anticipated Q4 2026 topline data from Part 3 of the Phase 1 trial of DA-1726 at 48 mg and 64 mg doses.
Company is also developing vanoglipel (DA-1241) for the treatment of MASH, alongside its DA-1726 cardiometabolic program.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.